NEW YORK, Dec. 11, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company"), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that the U.S. District Court for the District of Nevada has issued a temporary restraining order and associated injunction (the "Order") to enjoin Laidlaw & Company (UK) Ltd. and its principals, Matthew Eitner and James Ahern, from "continuing to disseminate false and misleading proxy materials." The Court order was issued in response to the previously announced lawsuit that Relmada filed against Laidlaw and Messrs. Eitner and Ahern as a result of their dissemination of materially false and misleading information in Laidlaw's attempt to take effective control of Relmada. Laidlaw, an investment brokerage firm, previously served as an investment banker to Relmada. Laidlaw and its principals have a history of violating U.S. financial regulations, which has resulted in numerous customer complaints, regulatory sanctions and monetary penalties. "We are pleased that the Court recognized the merits of our request and issued this order," said Sergio Traversa, Chief Executive Officer of Relmada. "We would prefer to focus our attention and resources on the continued development of Relmada's product portfolio, including the development of BuTab, for which we recently announced positive study results. However, we do not believe that it is in our stockholders' best interest to give effective control of the Company to Laidlaw and that doing so would be value destructive. This belief is evidenced by the adverse consequences related to our uplisting to NASDAQ due to the actions of Laidlaw's principals, Messrs. Eitner and Ahern, and their previous hand-picked director Dr. Nabil Yazgi, which are detailed in our December 7 press release. We believe Laidlaw's interests are very different from all other Relmada stockholders, and we will continue to take all appropriate actions to protect the Company and the interests of all Relmada stockholders." In issuing the Order, the Court found that "Relmada is likely to succeed on the merits because the False Solicitation contains material misstatements and omissions" and that "Relmada and its stockholders will suffer irreparable harm if [Laidlaw and its principals] are not enjoined from continuing to disseminate false and misleading proxy materials and required to retract or correct those materials."